Please login to the form below

Not currently logged in
Email:
Password:

Sprout Pharma

This page shows the latest Sprout Pharma news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... hypoactive sexual desire disorder. serotonin 5

Latest news

  • Valeant swoops on Sprout to claim female sexual disorder drug Valeant swoops on Sprout to claim female sexual disorder drug

    The ink was barely dry on the FDA's approval of Sprout Pharma's controversial 'little pink pill' Addyi before Valeant announced a $1bn deal to buy the company. ... The Sprout deal comes after its $11bn purchase of gastrointestinal drug specialist Salix

  • FDA panel backs Sprout Pharma's 'female Viagra' FDA panel backs Sprout Pharma's 'female Viagra'

    FDA panel backs Sprout Pharma's 'female Viagra'. Could be approved for HSDD in pre-menopausal women. ... drug. Sprout acquired rights to the programme in 2011 and says it hopes to market it under the Addyi trade name.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics